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Abstract Reticulons (RTNs) are a group of membrane-
associated proteins mainly responsible for shaping the
tubular endoplasmic reticulum network, membrane traf-
ficking, inhibition of axonal growth, and apoptosis. These
proteins share a common sequence feature, the reticulon
homology domain, which consists of paired hydrophobic
stretches that are believed to induce membrane curvature
by acting as a wedge in bilayer membranes. RTNs are
ubiquitously expressed in all tissues, but each RTN mem-
ber exhibits a unique expression pattern that prefers certain
tissues or even cell types. Recently, accumulated evidence
has suggested additional and unexpected roles for RTNs,
including those on DNA binding, autophagy, and several
inflammatory-related functions. These manifold actions of
RTNs account for their ever-growing recognition of their
involvement in neurodegenerative diseases like Alzhei-
mer’s disease, amyotrophic lateral sclerosis, multiple
sclerosis, as well as hereditary spastic paraplegia. This
review summarizes the latest discoveries on RTNs in
human pathophysiology, and the engagement of these in
neurodegeneration, along with the implications of these
findings for a better understanding of the molecular events
triggered by RTNs and their potential exploitation as next-
generation therapeutics.
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Introduction
Reticulons (RTNs) are a super-family of proteins named
after their principal subcellular localization at the endo-
plasmic reticulum (ER) (van de Velde et al. 1994; Oertle
and Schwab 2003; Yang and Strittmatter 2007). The family
originally came to prominence because of the proposed
role of one member, RTN 4A, as an inhibitor of neural
outgrowth and of axonal regeneration in the CNS
(GrandPre´ et al. 2000). However, studies that are more
recent have disclosed a key role of RTNs in shaping
intracellular membrane-bound organelles (especially the
ER) and have also highlighted the importance of these
proteins in the pathogenesis of neurodegenerative diseases.
Indeed, impairment of any of the processes controlled by
RTNs is somehow associated with neurodegeneration. For
instance, fluctuations of RTNs levels disrupt normal brain
functions in several neurodegenerative disorders, as well as
in schizophrenia (GrandPre´ et al. 2000; Yang and
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Strittmatter 2007). Whether our increased understanding of
normal and pathological roles of RTNs makes it possible to
design rational therapeutic approaches to target neurode-
generative diseases is also discussed in this review.
From Classification to Structural Organization of RTNs
Definition, Evolution, and Classification of RTNs
Reticulons are a family of morphogenic, ER membrane-
shaping proteins that stabilize highly curved ER membrane
tubules. They are all characterized by the conserved ret-
iculon homology domain (RHD), a sequence of 150–200
amino acid residues that is located at the C-terminal and is
highly significant for localization and function of the pro-
tein (Oertle and Schwab 2003). All RHD-containing pro-
teins apparently arose early in eukaryote evolution, with 4
RTN genes in mammals (RTN1–4), 2 in yeast (RTN1 and
RTN2), 21 and 17 in Arabidopsis thaliana and Oryza sa-
tiva plants, respectively (Oertle et al. 2003a). Their absence
in archaea or bacteria is strongly indicative of their origin
in response to the evolution of endo-membrane systems. A
nomenclature-based classification of RTNs has been pro-
posed, whereby in chordates the gene and corresponding
protein symbol is RTN (used throughout this manuscript),
whereas in non-chordate metazoans, it is RTNL (standing
for RTN-like) (Oertle et al. 2003a). In many species,
multiple RTN genes are present, and these appear to have
stemmed from duplications from a single common ancestor
(Bandtlow et al. 2004). The four mammalian genes
(RTN1–4) generate at least 11 splice variants. RTN1 yields
two major proteins, called RTN1A and RTN1C, and, to a
lesser extent, a third RTN1B variant. RTN2 gives rise to 3
proteins, called RTN2A, RTN2B, and RTN2C, whereas
RTN3 generates RTN3A and RTN3B. Finally, RTN4
yields 3 major isoforms (RTN4A, RTN4B, and RTN4C),
also referred to as NogoA, NogoB, and NogoC (Roebroek
et al. 1993; van de Velde et al. 1994; Geisler et al. 1998;
Roebroek et al. 1998; Moreira et al. 1999; Yang et al.
2000) (Fig. 1a).
The RHD and RTN Membrane Topology
The key feature of the RHD is the presence of two
unusually long hydrophobic regions (Fig. 1b), separated by
a 66 amino acid long, hydrophilic loop (also known as
Nogo66 loop), and followed by a short C-terminal tail (van
de Velde et al. 1994; Oertle and Schwab 2003; Yang and
Strittmatter 2007). The presence of a conserved RHD is
responsible for the commonality among functions of dis-
tinct RTNs and for their subcellular localization and
interaction with other proteins. Intriguingly, the fact that
RTNs do not display the canonical N-terminal ER-locali-
zation signal, and the relatively longer sequence of the two
hydrophobic regions (*30–35 amino acids, compared to a
Fig. 1 Classification and
topology of mammal RTNs.
a Schematic representation of
RTNs. The scale bar
corresponds to the length in
amino acids of each RTN. The
reticulon homology domain is
indicated by black and blue
boxes, where the black boxes
represent the hydrophobic
regions. N-Terminal regions of
the different RTN isoforms are
colored. b A schematic diagram
illustrating the possible
membrane topologies of RTNs.
Based on predictions by
computer programs or on
biochemical assessments, RTNs
may assume several topological
orientations within the lipid
bilayer. See text for details
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typical *20 amino acids transmembrane domain of),
suggests that RTN retention within ER membranes could
be mainly due to the structural conformation or topology of
RHD (van de Velde et al. 1994; Oertle and Schwab 2003;
Yang and Strittmatter 2007). This hypothesis led to early
speculations that the hydrophobic domains might ‘‘double
back’’ within the membrane, forming hairpin loops into the
outer leaflet of the lipid bilayer responsible for membrane
bending (Oertle and Schwab 2003). However, other con-
formations are possible and, based on predictions by in
silico analysis, RTNs may adopt a different folding which
is able to flip–flop within the lipid bilayer due to the pre-
sence of charged residues within the two hydrophobic
domains (Fig. 1b). These domains are indeed long enough
to loop back within the lipid bilayer, thus giving rise to
several alternative orientations of RTNs (Oertle et al.
2003a, b, c; Voeltz et al. 2006; He et al. 2007; Sparkes
et al. 2010). Although there is some evidence that RHD
membrane topology can be influenced by protein sequence
in the hydrophilic loop and in the N-terminal domain (He
et al. 2007), future biochemical studies are deemed nec-
essary to determine the actual topology of RTNs and the
identity of factors that can affect it.
N-Terminal Domain of Mammalian RTNs
In contrast to RHD, N-terminal regions of RTNs are not
conserved and show dramatic differences in terms of length
and sequence, even within RTNs isoforms (Oertle and
Schwab 2003; Yang and Strittmatter 2007). In some RTNs,
like RTN1C, RTN2C, and RTN4C, the N-terminal
sequences are extremely short, with the bulk of the protein
mainly consisting of RHD. In others, like RTN1A/B,
RTN2A/B, RTN3A, and RTN4A/B, the N-terminal regions
are much larger and are likely to confer specific biological
functions. Somewhat surprisingly, no recognized protein
domains have been identified so far in N-terminal regions,
whose function remains mostly unknown. However, N
terminus of RTN4A and RTN4B is rich in proline and
contains large unstructured regions (Li and Song 2007).
Furthermore, N terminus of all RTN4 isoforms lacks a
specific signal sequence for ER translocation, accounting
for their presence both in the ER and at the cell surface.
The presence of such unstructured N-terminal domains in
RTN4A/B allows them to form multiprotein structures and
to carry out alternative functions. A role in mediating the
interaction with other functional partners has been docu-
mented and may contribute to the facilitation of the binding
of Nogo66 to its receptor (as explained later) (Hu et al.
2005) or the degradation of RTNs. Indeed, phosphorylation
of the N terminus of RTN4B by cyclin-dependent kinases 1
and 2 renders the protein susceptible to cleavage by cas-
pase-7 (Schweigreiter et al. 2007).
RTNs as Mediators of Physiological Functions
The ubiquitous expression of RTNs suggests a general role
in the functioning of this organelle. However, although
ubiquitously expressed in all tissues, each individual RTN
can still exhibit a degree of tissue- or cell-specific pattern
(Oertle and Schwab 2003). Furthermore, many cell types
express more than one RTN, suggesting that some of these
proteins may have additional specific functions beyond
those at the ER. In the following sections, we shall outline
what is known about common and distinct roles of RTNs
(Fig. 2), except for RTN2 for which no specific activity has
been unveiled yet. Commonalities and specificities of
RTNs in human pathophysiology are also summarized in
Table 1.
Common Functions of RTNs
ER Shaping and Morphogenesis
A major advance in our understanding of the function of
RTNs came with the identification of members of the RTN
family as key proteins involved in shaping and morpho-
genesis of the ER. This role of the RTNs has been recently
discussed in extensive reviews (Shibata et al. 2009; Hu
et al. 2011; Park and Blackstone 2010), thus here we shall
briefly summarize it. RTNs interact with members of
another class of proteins, the DP1/yop1p/REEP family
(referred to as REEPs throughout this article) (Voeltz et al.
2006). Both RTNs and REEPs localize at the highly curved
regions of ER tubules, and in many species, their cellular
depletion causes defects in the formation of the tubular ER;
conversely, their overexpression leads to increased ER
tubulation (Voeltz et al. 2006; Sparkes et al. 2010;
O’Sullivan et al. 2012). In addition, in vitro reconstitution
experiments have shown that RTN (e.g., Rtn1p) or REEP
(e.g., Yop1p) is sufficient to tubulate proteoliposomes (Hu
et al. 2008). Similarly, to RTNs, REEPs have a conserved
double hairpin membrane domain that is critical to confer
the ability to shape ER tubules (Voeltz et al. 2006; Hu et al.
2008; Zurek et al. 2011). These observations have led to a
model for ER tubule formation whereby RTNs and REEPs
act synergistically to trigger and stabilize membrane cur-
vature by hydrophobic wedging. In this process, the hairpin
membrane domains displace lipids from the outer layer
better than from the inner layer (Hu et al. 2011). It has been
proposed that oligomerized RTNs and REEPs act as a
scaffold to impose a cylindrical structure on the membrane
curvature, thus generating a tubule (Hu et al. 2008). By a
similar mechanism, the same proteins are also involved in
generating the highly curved edges of ER sheets (Shibata
et al. 2010). Two additional classes of proteins act in
concert with RTNs and REEPs during ER morphogenesis:
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atlastins, large GTPases that mediate homotypic fusion of
ER tubules, and spastin, an ATPase that separates micro-
tubules, particularly in relation to membrane modeling
events (Errico et al. 2002; Orlacchio et al. 2004; Connell
et al. 2009; Hu et al. 2009; Bian et al. 2011; Morin-Leisk
et al. 2011; Moss et al. 2011; Liu et al. 2012; Lumb et al.
Fig. 2 Diverse functions and molecular mechanisms of RTNs. The
hydrophobic domains of RTNs can interact with other transmembrane
proteins involved in ER shaping and morphogenesis (REEPs,
atlastins, spastin) and membrane trafficking (SNARE, AP2), they
can directly bind DNA or regulate apoptosis and autophagy through
caspases activation and control of Bcl-2-family proteins. The majority
of the diverse functions of RTNs occur through the interaction of the
hydrophilic loop Nogo66 with its receptor NgR, or by the interaction
of their N-terminal tail with a purported receptor. In case of RTN4,
these interactions mostly lead to Rho signaling activation. See text for
details
Table 1 Role of RTNs in human pathophysiology
Reticulon Localization Common functions Specific functions Neurodegenerative
diseases
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2012). In line with this, the expression of an ATPase-
defective spastin results in extensive tubulation of the ER,
highlighting its role as a microtubule-severing protein
during ER shaping (Connell et al. 2009). Both atlastins and
spastin possess long hydrophobic domains that are pro-
posed to act as hairpin wedges, and both interact with
RTNs and REEPs as well as with each other (Sanderson
et al. 2006; Park et al. 2010; Montenegro et al. 2012).
Membrane Trafficking
Although RTNs are principally located within ER mem-
branes, they have also been described at the level of Golgi
and plasma membranes, suggesting that they may act also
at these sites. In this context, it is interesting that several
studies suggest that RTNs may be involved in the secretory
pathway. For example, RTN1C co-immunoprecipitates
with a variety of SNARE proteins that are engaged in
regulated secretion, and ectopic expression of a fragment of
RTN1C in PC12 cells leads to an increased rate of growth
hormone release (Steiner et al. 2004). Similarly, RTN2B is
a positive regulator of the delivery of the neuronal EAAC1
glutamate transporter from the ER to the cell surface, via a
mechanism that appears to facilitate exit of the transporter
from ER (Liu et al. 2008). RTN3 has been implicated in
early phases of the secretory pathway, because its over-
expression in HeLa cells interferes with both anterograde
and retrograde transport between ER and Golgi (Wakana
et al. 2005). A caveat is that often the functional data rely
on overexpression studies, but they lack evidence on the
role of constitutive proteins under more physiological
conditions. Therefore, additional experiments should be
performed to better assess the in vivo relevance of these
findings.
Apoptosis
Several lines of evidence indicate that RTNs are involved
in cell death pathways, most notably in ER stress-induced
apoptosis. Interestingly, RTN1C or RTN4A/B overex-
pression induces per se apoptosis by inhibiting the apop-
totic inhibitors Bcl-XL and/or Bcl-2; instead, RTN1C,
RTN3, or RTN4B overexpression causes ER stress-medi-
ated apoptosis paralleled by Ca2? depletion from ER stores
(Tagami et al. 2000; Kuang et al. 2005; Kuang et al. 2006;
Tufi et al. 2008). Consistently, RTN1C-overexpressing
neuroblastoma cells show a significant increase in their
susceptibility to cell death upon ER stress induction (Di
Sano et al. 2007). In addition, in HeLa cells, RTN3 causes
the activation of caspases-3 and caspases-12, along with
the collapse of mitochondrial membrane potential and the
release of cytochrome c (Xu et al. 2006). RTN3 also
enhances TRAIL-induced apoptosis through the induction
of DR5 expression in human renal cancer cells (Lee et al.
2009). However, literature data on the role of RTNs in
apoptosis are partly controversial, inasmuch as not only
RTN4B may exert anti-apoptotic functions (Oertle et al.
2003b; Schweigreiter et al. 2007), but ER stress-mediated
RTN3 up-regulation can also be protective against several
insults by contributing to Bcl-2 translocation to the mito-
chondria (Wan et al. 2007). Indeed, RTN3 can interact with
Bcl-2 both in vitro and in vivo and can mediate its accu-
mulation in mitochondria, thus modulating its anti-apop-
totic activity (Zhu et al. 2007).
Distinct Roles of RTNs
RTN1
The first member of the RTNs family to be identified in
1993 is mainly expressed in neurons and cells of neuro-
endocrine tissues (Roebroek et al. 1998). The RTN1C
isoform is the most studied and has long been considered a
marker of neuronal differentiation because its expression is
increased upon differentiation in several neuroblastoma
cell lines (Wieczoerk and Hughes 1991; Hens et al. 1998).
In the C-terminal region of RTN1C, the GAKRH sequence
(a signature of H4 histone) confers a strong ability to bind
and condense DNA. Such a binding activity of RTN1C is
regulated by acetylation/deacetylation and is coupled to
inhibition of HDAC activity (Fazi et al. 2009; Melino et al.
2009; Nepravishta et al. 2010). The apparently unique
ability of RTN1 to affect epigenetic modifications is
believed to play a major role in its biological functions.
The first clues for a functional role of N-terminal domains
of RTN1 isoforms came very recently from two interesting
studies. On one hand, it was reported that RTN1C was able
to modulate the nitrosylation-dependent activity of protein
disulfide isomerase, which is involved in cellular defense
against ER stress-related protein misfolding (Bernardoni
et al. 2013). Kaya et al. (2013) identified the intracellular
calcium release channel ryanodine receptor 2 (RyR2) as a
novel binding partner of RTN1A in neurons both in vitro
and in vivo and showed a RTN1A-dependent inhibitory
effect on the RyR2 activity, with potential implication in
neurotransmitter release and in aging-related Ca2?
dysregulation.
RTN3
It was firstly isolated from the retina and later shown to
have a widespread expression, with the highest levels in the
brain (Moreira et al. 1999; Qi et al. 2003; Cai et al. 2005).
RTN3 expression in the optic and olfactory nerve during
both developmental and adult stages, along with its co-
localization with synaptophysin in the tubulovesicular
Neuromol Med (2014) 16:3–15 7
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structures in the developing axon of cultured cortical
neurons, suggested an important role in axonal develop-
ment (Kumamaru et al. 2004). Moreover, RTN3 has been
recently linked to autophagy, because its depletion
increased autophagy induction in human prion-over-
expressing neuroblastoma cells, with subsequent enhance-
ment of the clearance of prion aggregates (Chen et al.
2011). In particular, RTN3 inhibited Beclin-1-dependent
autophagy by promoting the formation of the inactive Bcl-
2/Beclin-1 complex (Chen et al. 2011). Yet, there is no
evidence that other RTNs, despite they also interact with
Bcl-2, may be implicated in autophagy. In yeast, combined
deletion of a RTN with the REEP homolog yop1p leads to
inhibition of the replication of positive-strand RNA viruses
(Diaz et al. 2010). The latter replicate in curved intracel-
lular membrane compartments that are absent when
membrane-shaping proteins are defective. In support of the
idea that membrane shaping by RTNs is important in viral
replication, studies in mammalian cells have shown that
RTN3 interacts with viral replication components and is
necessary and sufficient for enteroviral replication (Tang
et al. 2007). Recently, the role of RTN3 has also been
associated with neuritic dystrophy and cognitive deficits,
with particular reference to diabetic-induced dementia (Shi
et al. 2013; Deng et al. 2013; Zhao et al. 2013).
RTN4
Commonly known as Nogo, it is undoubtedly the most
studied member of the RTN family. The RTN4 isoforms
RTN4A, RTN4B, and RTN4C have very different distri-
bution patterns throughout the nervous system, as well as in
peripheral body districts. RTN4A is largely, but not
exclusively, expressed in the nervous system, in particular
in cerebral cortex, hippocampus, diencephalon, cerebel-
lum, and spinal cord. Outside the CNS, RTN4A is
expressed in skin, skeletal muscle, heart as well as in
certain immune cells, in particular macrophages (Schwab
2010). RTN4B is expressed in many tissues, including the
central and peripheral nervous systems, as well as at sev-
eral peripheral sites such as vascular endothelial cells and
inflammatory cells (Acevedo et al. 2004; Schwab 2010).
RTN4C expression, instead, is poorly documented, mainly
due to the lack of human-specific antibodies and probes.
However, it is highly expressed in skeletal muscle, in some
types of neurons of rat CNS, such as cerebellar Purkinje
cells, and weakly expressed in liver and kidney (Josephson
et al. 2001; Schwab 2010). Ample evidence has supported
RTN4 (especially the RTN4A isoform) as an important
agent in inhibiting neurite outgrowth and axonal regener-
ation (Chen et al. 2000; GrandPre´ et al. 2000; Prinjha et al.
2000; Kim et al. 2003; Oertle et al. 2003c; Reindl et al.
2003; Simonen et al. 2003; Karnezis et al. 2004). The role
of RTN4 in these processes has been extensively reviewed
and will be briefly summarized here. The current model
suggests that the extracellular hydrophilic Nogo66 loop is
expressed on the surface of oligodendrocytes or Schwann
cells and binds to an axonal Nogo66 receptor (NgR)
(O’Neill et al. 2004). Interestingly, since NgR is localized
on the outer layer of the plasma membrane and lacks a
transmembrane domain, its signaling cascade engages
several transducers and is strictly dependent on down-
stream activation of Ras homologous gene family, member
A (Rho-A) (Ellezam et al. 2002; Fournier et al. 2003).
These signaling transducers include the neurotrophin
receptor p75, the transmembrane protein LINGO-1, the
orphan tumor necrosis factor family member TAJ/TROY
(Wang et al. 2002; Mi et al. 2005; Shao et al. 2005). Of
notice, several studies have recently reported that Nogo
proteins play a crucial role in inflammation-related pro-
cesses, most of them linked to leukocyte recruitment at
sites of acute or chronic inflammation (Acevedo et al.
2004; Yu et al. 2009; Wright et al. 2010; Di Lorenzo et al.
2011; Schanda et al. 2011), inhibition of endothelial cell
migration (Wa¨lchli et al. 2013), liver pathophysiology
(Zhang et al. 2011; Gao et al. 2013), as well as regulation
of synaptic plasticity and cognitive functions (Tews et al.
2013; VanGuilder Starkey et al. 2013). These novel find-
ings seem to be independent of the RHD motif; yet, the
underlying molecular events are likely to rely on the NgR-
induced RhoA pathway and on the reported capability of
Nogo proteins to associate with cytoskeletal structures in
immune cells (Schanda et al. 2011). Interestingly, leuko-
cytes extravasation across the blood–brain barrier and their
subsequent accumulation at sites of injury is now recog-
nized as a hallmark of neurodegenerative diseases (Rezai-
Zadeh et al. 2009; Schwartz et al. 2009).
The Role of RTNs in the Pathological Processes
of Neurodegenerative Diseases
Alzheimer’s Disease
Alzheimer’s disease (AD) is probably the most common
neurodegenerative disease and, although its etiology is still
unclear, it is characterized by the presence of brain amyloid
plaques and neurofibrillary tangles whose accumulation
ultimately leads to extensive neuronal loss and progressive
decline of cognitive function (Chiurchiu` and Maccarrone
2011; Huang and Mucke 2012). All 4 human RTN proteins
seem to be involved in AD, inasmuch as beta-site amyloid
precursor protein-cleaving enzyme1 (BACE1), the b-
secretase responsible for the cleavage of the amyloid pre-
cursor protein (APP) into b-amyloid peptide (Ab) was
found to co-immunoprecipitate with RTN1, RTN2, RTN3,
8 Neuromol Med (2014) 16:3–15
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and RTN4 (He et al. 2004). Yet, research efforts have been
focused mainly on RTN3 and RTN4, which were shown to
interact with BACE1, most likely through the RHD (He
et al. 2004; Murayama et al. 2006). In vitro overexpression
of RTN3 reduced the levels of Ab produced by HEK-293
cells, and conversely, knockdown of RTN3 by RNA
interference increased Ab levels, consistent with the idea
that RTN3 inhibits BACE1. Notably, in a subtractive
hybridization screening, human RTN3 was found to be
downregulated in the temporal lobes of AD patients (Yo-
kota et al. 2006). Although the two-transmembrane-domain
tertiary structure of RTN3 and RTN4 seems to critically
affect BACE1 enzymatic activity (Kume et al. 2009a, b),
the relevance of these RTNs for AD pathology and their
exact role remains controversial and thus yet to be estab-
lished. On the one hand, a mechanism by which RTN3 may
function as a negative modulator of Ab production has
been proposed and is such that the association of RTN3–
BACE1 may alter its trafficking itinerary, thus affecting
BACE1 enzymatic activity more markedly in post-Golgi
compartments like the endosomes (Small and Gandy 2006;
Shi et al. 2009). On the other hand, RTN3 seems to act as a
marker for AD, inasmuch as it has been shown to oligo-
merize and accumulate in a subpopulation of dystrophic
neuritis in AD postmortem brain (Hu et al. 2007). Con-
sistently, transgenic mice overexpressing RTN3 develop
dystrophic neuritis that are morphologically similar to
those observed in AD brains and that correlate with the
formation of RTN3 aggregates in susceptible brain regions
(Hu et al. 2007). However, these findings are in conflict
with those by Kume et al. (2009a, b), in which, although
reporting that RTN3 subcellularly co-localizes with
BACE1, no significant differences in its expression levels
were observed between control and AD brains.
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disease characterized by the death of both upper
and lower motor neurons of the brain, brain stem, and
spinal cord, overall leading to progressive weakness and
atrophy of skeletal muscles (Mitchell and Borasio 2007;
Chiurchiu` and Maccarrone 2011). Both in postmortem
muscular samples of ALS patients and in ALS mouse
models expressing human superoxide dismutase (SOD)
with a disease-causing dominant mutation, differential up-
and down-regulation of RTN4A/B and RTN4C mRNA
compared with wild-type mice was reported (Dupuis et al.
2000). Levels of RTN4A (and to a lesser extent of RTN4B)
mRNA increased in pre-symptomatic animals, whereas
RTN4C was highly expressed in asymptomatic mice only
(Dupuis et al. 2000). Indeed, the levels of RTN4A and
RTN4B, which are barely detectable in adult muscles,
increased in ALS mice and correlated with disease severity
(Jokic et al. 2005), whereas the levels of the highly
expressed RTN4C isoform decreased (Dupuis et al. 2002).
Beyond these expression and mechanistic studies, several
functional evidences also emerged. For instance, a link
between the early overexpression of RTN4A in ALS
muscle fibers was found and consisted in an impairment of
the neuromuscular junction, ultimately leading to motor
neuron degeneration (Jokic et al. 2006). Additionally,
RTN4A was protected from SOD1-dependent ASL by
contributing to the correct functioning of the ER (Yang
et al. 2009). Conversely, several reports indicate that
RTN4A expression is not unique to this disorder (Wojcik
et al. 2006; Pradat et al. 2007; Harel et al. 2009; Askanas
et al. 2007). Overall, there is a general consensus that we
have to be cautions as to consider RTN4 as a specific
biomarker for ALS, thus questioning whether this protein
could be a possible candidate target for novel drugs against
the disease (Ta˚gerud et al. 2007).
Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory, pro-
gressive, and degenerative disorder characterized by
intermittent episodes of demyelination and axonal loss or
damage in the CNS. Although its etiology has not been
fully elucidated yet, it is likely that both genetic and
environmental components play a crucial role in disease
onset and progression, and it is now well recognized that
immunological mechanisms are the initial trigger of MS
(Noseworthy et al. 2000; Chiurchiu` and Maccarrone 2011;
Chiurchiu` et al. 2013). Autoantibodies against RTN4A
have been found in serum and cerebrospinal fluid of
patients with MS, especially in those with relapsing-
remitting rather than chronic progressive MS (Reindl et al.
2003). Interestingly, administration of exogenous anti-
RTN4A antibodies protected against demyelination in the
experimental autoimmune encephalomyelitis (EAE) mouse
model of MS, inasmuch as it suppressed inflammatory
responses in these animals (Karnezis et al. 2004). Consis-
tently, RTN4 knockout mice showed a significantly
delayed onset of EAE development, and passive immuni-
zation with anti-Nogo immunoglobulin suppressed
inflammatory processes associated with EAE (Karnezis
et al. 2004). Given the importance of RTN4 in neurite
growth within the brain, these data suggest that its block-
ade could be beneficial to preserve or perhaps even restore
neuronal integrity after demyelination and axonal loss or
damage during MS. However, vaccination with Nogo66-
derived peptides may prevent but also promote encephali-
togenic reactions, depending on the type of the recruited
immune response (Fontoura et al. 2004). Furthermore,
analyses of demyelinating lesions in MS patients
Neuromol Med (2014) 16:3–15 9
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demonstrated that RTN4A is highly expressed in oligo-
dendrocytes, while its NgR receptor appears specifically in
reactive astrocytes and microglia/macrophages (Satoh et al.
2005). The biological meaning of this distinct expression
pattern remains unknown, but it could influence disease
pathogenesis and future therapeutic approaches. Indeed
recent evidence supports the concept that targeting RTN4
signaling in MS could be a promising therapeutic approach
(Lee and Petratos 2013). In fact, impairment of LINGO-1
or blockade of its pathway, as well as silencing of RTN4A,
promoted functional recovery and limited clinical severity
by stimulating axonal growth and repair in MOG35–55- and
myelin basic protein-induced EAE models, ultimately
improving the functional deficits caused by immune-med-
iated axonal damage (Mi et al. 2007; Yang et al. 2010). The
potential mechanism of such therapeutic effect likely
involves a reduction in the NgR-dependent signaling which
limited the activation of the phosphorylation of CRMP-2, a
crucial tubulin-associated protein that regulates axonal
growth, thus preventing axonal degeneration and neuro-
logical decline (Petratos et al. 2012).
Hereditary Spastic Paraplegia
Hereditary spastic paraplegia (HSP) includes a large and
diverse group of genetic disorders whose main feature is
progressive spasticity and weakness in the lower limbs, as a
result of continuous distal axonopathy caused by defects in
the mechanisms that transport proteins and substances
along the axons (Fink 2013; Blackstone et al. 2011;
Blackstone 2012). At least four autosomal dominant HSP
are caused by mutations in genes encoding proteins
involved in ER morphogenesis and that bear an intra-
membrane hairpin loop responsible for the curvature of ER
membranes and for their reciprocal interactions. These
include spastin, the most commonly mutated protein in
HSP, atlastin-1, REEP1, and RTN2 (Wakana et al. 2005;
Orso et al. 2009; Blackstone 2012). Not surprisingly, sev-
eral members of the RTN family have been shown to
interact with the latter proteins. Indeed, RTN3 and RTN4
interact with atlastin-1 (Hu et al. 2009), whereas RTN1 and
RTN3 have been found to interact with spastin (Mannan
et al. 2006a, b). The evidence that mutations in the RTN2
gene cause the autosomal dominant spastic paraplegia 12
(SPG12) was very recently demonstrated by our group
(Montenegro et al. 2012). We have also shown that RTN2
interacts with spastin, an interaction that requires the pre-
dicted hairpin membrane domain in the latter protein. Thus,
unlike other RTNs, whose involvement in neurodegenera-
tive diseases is still at a mechanistic level, this is the first
genetic evidence that a member of the RTNs family
directly causes a specific disorder, with haploinsufficiency
of RTN2 likely being the molecular pathological mecha-
nism for axonopathy (Fig. 3). In keeping with this, the
Drosophila melanogaster ortholog of the HSP gene RTN2
(called RTN-like 1 gene) was found to be required for
organization of ER and of distal motor axons, thus sup-
porting the concept that HSP can be caused by axonal ER
impairment (O’Sullivan et al. 2012). These results dem-
onstrate that RTN2 protein participates in the network of
Fig. 3 Role of RTN2 in HSP. A
schematic of the RTN2 gene is
drawn to scale with the
corresponding conserved
protein domains and the
identified mutations (red
crosses). Haploinsufficiency of
RTN2 cause the autosomal
dominant spastic paraplegia 12
(SPG12) and is a likely
mechanism for the injury of the
distal axon (axonopathy) with
subsequent retrograde or ‘‘dying
back’’ axonal degeneration
toward the neuronal cell body.
See text for details
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HSP proteins involved in ER shaping and provide further
direct evidence not only that correct ER shaping may be
important in general axonal maintenance, but also that
abnormal ER morphogenesis is a potential pathogenic
mechanism in HSP. These findings will set the basis for
future studies aimed at determining how abnormal ER
morphogenesis causes axonal degeneration.
Concluding Remarks and Future Directions
The engagement of RTNs in neurodegeneration is a rather
challenging issue, because of the large number of isoforms
of each RTN, and the fact that all of these proteins are
almost equally expressed within the brain, where they share
common functions. This scenario is further complicated by
the yet unclear molecular events triggered by RTNs.
Nonetheless, although the mechanism by which abnormal
ER morphogenesis can cause degeneration of neuronal
cells is unknown, the crucial role of these proteins in ER
functioning is apparent and it is not surprising that most of
neurodegenerative disorders are related to ER-associated
dysfunctions, including protein misfolding and cell death.
Of note, the concept that in biology the same protein
acquires multiple roles during evolution holds true also in
the case of RTNs, which initially emerged as a family of
neuroendocrine-specific proteins whose function was only
attributed to their RHD topology and are now being rec-
ognized as modulators of several other functions possibly
alleged to the N-terminal domain. The recent findings of a
role for RTNs in the modulation of vascular and immune
functions appear to be consistent with this view, as the
isoforms which bear the longest N-terminal regions are
indeed the most active in these processes. Future studies
focused on the role of each RTN protein in distinct
peripheral regions of the body, in health and disease, will
provide valuable insights into their expanding role in both
neurodegeneration and inflammation. Furthermore, the
emerging findings summarized here suggest the existence
of a complex RTN signaling network that affects immune
functions by engaging NgR or a yet unidentified N-termi-
nal receptor. Thus, additional studies on the signaling
impact of N-terminal regions of RTNs are needed in order
to provide deeper insights into the roles of their ancient
receptors in the generation, plasticity, and pathology of the
nervous system, as well as in immune-mediated processes
typical of neurodegenerative diseases. Accordingly, the
different RTN expression patterns between healthy and
diseased tissues could represent one of the most interesting
keys for designing new therapeutics. However, an RTN-
based pharmacological approach is far from being on the
way, because many questions concerning the exact role of
RTNs await to be answered, and further investigations are
needed to confirm whether these proteins may be potential
therapeutic targets in neurodegenerative diseases. For
instance, one difficulty in designing appropriate drugs that
target RTN3 in AD is the fact that both increases and
decreases of this protein have been reported in this disor-
der. Furthermore, future pharmacological strategies should
also take into account the manifold physiological functions
of RTNs in order to provide an effective therapeutic
treatment. The genetic correlation of RTN2 in the induc-
tion of SPG12 makes it the only member of the RTNs
family that could hitherto be potentially targeted. On a final
note, the discovery that RTN1C is a DNA-binding protein
seems of particular interest, because it adds the new
dimension of epigenetic regulation of gene expression to
the already complete machinery involved in neurodegen-
erative processes.
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